

## A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors

Jordi Rodon<sup>1,\*</sup>, Hussein A. Tawbi<sup>2,\*</sup>, Anne L. Thomas<sup>3</sup>, Ronald G. Stoller<sup>2</sup>, Christian P. Turtschi<sup>4</sup>, Jose Baselga<sup>5</sup>, John Sarantopoulos<sup>6</sup>, Devalingam Mahalingam<sup>6</sup>, Yaping Shou<sup>7</sup>, Melissa A. Moles<sup>7</sup>, Lin Yang<sup>7</sup>, Camille Granvil<sup>8</sup>, Eunju Hurh<sup>7</sup>, Kristine L. Rose<sup>8</sup>, Dereck D. Amakye<sup>8</sup>, Reinhard Dummer<sup>4</sup>, and Alain C. Mita<sup>6,\*</sup>

### Abstract

**Purpose:** This phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent inhibitor of hedgehog signaling, in patients with advanced solid tumors.

**Experimental Design:** Oral sonidegib was administered to 103 patients with advanced solid tumors, including medulloblastoma and basal cell carcinoma (BCC), at doses ranging from 100 to 3,000 mg daily and 250 to 750 mg twice daily, continuously, with a single-dose pharmacokinetics run-in period. Dose escalations were guided by a Bayesian logistic regression model. Safety, tolerability, efficacy, pharmacokinetics, and biomarkers in skin and tumor biopsies were assessed.

**Results:** The MTDs of sonidegib were 800 mg daily and 250 mg twice daily. The main DLT of reversible grade 3/4 elevated serum creatine kinase (18% of patients) was observed at doses  $\geq$  the MTD in an exposure-dependent manner. Common grade 1/2 adverse events included muscle spasm, myalgia, gastrointestinal toxicities, increased liver enzymes, fatigue, dysgeusia, and alopecia. Sonidegib exposure increased dose proportionally up to 400 mg daily, and displayed nonlinear pharmacokinetics at higher doses. Sonidegib exhibited exposure-dependent reduction in GLI1 mRNA expression. Tumor responses observed in patients with medulloblastoma and BCC were associated with evidence of hedgehog pathway activation.

**Conclusions:** Sonidegib has an acceptable safety profile in patients with advanced solid tumors and exhibits antitumor activity in advanced BCC and relapsed medulloblastoma, both of which are strongly associated with activated hedgehog pathway, as determined by gene expression. *Clin Cancer Res*; 20(7); 1900–9. ©2014 AACR.

### Introduction

The hedgehog signaling pathway plays a key role during embryo-fetal development of the brain, bones, and

muscles (1). During the postnatal period and adulthood, hedgehog pathway activity is involved in the regulation of bone development, tissue maintenance and repair, and maintenance of stem cell populations (hair follicles; refs. 1 and 2). Aberrant hedgehog pathway activation has been linked with the pathogenesis of many human cancers through hedgehog ligand-dependent and ligand-independent mechanisms.

Genetic alterations, including loss-of-function mutations in the negative regulators patched 1 (PTCH1) and/or suppressor of fused (SUFU), or less frequently gain-of-function mutations in the positive regulator Smoothened (SMO), lead to ligand-independent pathway activation and have been linked to basal cell carcinoma (BCC), medulloblastoma, and rhabdomyosarcoma (2). Overexpression of hedgehog ligand has been observed in pancreatic, colorectal, lung, breast, prostate, esophageal, and gastric tumors (2). Therefore, the hedgehog pathway has become an attractive therapeutic target. Inhibitors targeting SMO, including vismodegib, which is approved by the U.S. Food and Drug Administration for the treatment of metastatic or locally advanced BCC, are currently being investigated in clinical trials (3–9).

**Authors' Affiliations:** <sup>1</sup>Vall d'Hebron Institut d'Oncologia and Universitat Autònoma of Barcelona, Barcelona, Spain; <sup>2</sup>University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; <sup>3</sup>University of Leicester, Leicester, United Kingdom; <sup>4</sup>University Hospital of Zürich, Zürich, Switzerland; <sup>5</sup>Memorial Sloan-Kettering Cancer Center, New York, New York; <sup>6</sup>Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas; <sup>7</sup>Novartis Institutes for BioMedical Research, Cambridge, Massachusetts; and <sup>8</sup>Novartis Pharmaceuticals Corporation, East Hanover, New Jersey

**Note:** Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Y. Shou and D.D. Amakye are no longer associated with Novartis.

\*J. Rodon, H.A. Tawbi, and A.C. Mita contributed equally to this article.

**Corresponding Author:** Hussein Tawbi, University of Pittsburgh Cancer Institute, Division of Hematology/Oncology, 5150 Centre Avenue, Pittsburgh, PA 15232. Phone: 412-648-6578; Fax: 412-648-6579; E-mail: tawbih@upmc.edu

doi: 10.1158/1078-0432.CCR-13-1710

©2014 American Association for Cancer Research.

### Translational Relevance

Aberrant hedgehog pathway activity has been linked to the pathogenesis of many cancers. The results of this phase I trial further advance the emerging clinical experience of hedgehog pathway inhibitors in patients with cancer. Oral sonidegib (LDE225) blocks the hedgehog pathway by selective inhibition of smoothened (SMO). Sonidegib exhibits an acceptable safety profile, exposure-dependent target inhibition, and clinically relevant antitumor effect in patients with locally advanced or metastatic basal cell carcinoma (BCC) and relapsed medulloblastoma. The toxicities identified are manageable and reversible upon discontinuation of treatment. Furthermore, a five-gene hedgehog signature assay demonstrated a strong association between tumor responses and hedgehog pathway activation, thus supporting its use as a patient selection tool in future studies. These data support ongoing clinical investigations of sonidegib as a single agent in BCC and hedgehog pathway-activated medulloblastoma, and as a combination partner with other agents in other malignant disease settings.

Sonidegib (LDE225), N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-40-(trifluoromethoxy)biphenyl-3-carboxamide, a novel selective inhibitor of SMO, was identified in a cell-based high-throughput screen (Supplementary Fig. S1; ref. 10). Sonidegib demonstrated high tissue penetration (including blood-brain barrier) and good oral bioavailability in preclinical studies (10). Oral administration of sonidegib in mouse medulloblastoma models *Ptch*<sup>+/-</sup> *p53*<sup>-/-</sup> and *Ptch*<sup>+/-</sup> *Hic1*<sup>+/-</sup> (hypermethylated in cancer 1) resulted in complete suppression of glioma-associated oncogene homolog 1 (GLI1) and tumor regression, suggesting targeted inhibition of hedgehog signaling (11).

We report results from a first-in-human, dose-escalation, phase I study with sonidegib in adult patients with advanced solid tumors. The study population was enriched with patients with locally advanced or metastatic BCC and relapsed medulloblastoma. This study established the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of continuous daily oral sonidegib administration. In addition, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity were assessed.

### Patients and Methods

#### Patient population

Adult patients with histologically or cytologically confirmed advanced solid tumors, including medulloblastoma, whose disease progressed despite standard therapy or for whom no standard therapy was available were eligible. Other key inclusion criteria were measurable or evaluable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.0; ref. 12) or the Neuro-Oncology Criteria for Tumor Response (medulloblastoma only; refs. 13 and 14) and Eastern Cooperative Oncology Group (ECOG)

performance status  $\leq 2$ . In addition, all patients must have had adequate bone marrow (absolute neutrophil count  $\geq 1.5 \times 10^9/L$ , hemoglobin  $\geq 9$  g/dL, and platelets  $\geq 100 \times 10^9/L$ ), liver (serum total bilirubin  $\leq 1.5 \times$  upper limit of normal [ULN] and aspartate aminotransferase and alanine aminotransferase  $\leq 2.5 \times$  ULN or  $\leq 5.0 \times$  ULN if liver metastases are present), and kidney function (serum creatinine  $\leq 1.5 \times$  ULN or 24-hour creatinine clearance of  $\geq 50$  mL/min). Patients were excluded if they had a history of a brain tumor or brain metastases (except relapsed medulloblastoma), clinically significant cardiac disease, or gastrointestinal dysfunction that might impair sonidegib absorption. Treatment with strong inhibitors or inducers of cytochrome P450 (CYP) 3A4/5 or drugs metabolized by CYP2B6 or CYP2C9, which have a narrow therapeutic index, was prohibited during the study.

All patients provided written informed consent before enrollment. The study followed the ethical principles of the Declaration of Helsinki, the International Conference on Harmonisation Guideline for Good Clinical Practice, and local regulations (European Directive 2001/20/EC and US Code of Federal Regulations Title 21). The protocol and amendments were approved by the institutional review board, independent ethics committee, or research ethics board at each center.

#### Study design

The primary objective of this dose escalation, multicenter, open-label phase I study was to determine the MTD and DLTs of oral sonidegib, administered on a continuous daily schedule. Additional objectives included safety, pharmacokinetics, pharmacodynamics, and antitumor activity. During dose escalation, all patients received a single oral dose of sonidegib in a 7-day pharmacokinetic run-in period to characterize the pharmacokinetic profile of sonidegib. Once the MTD was determined for the once-daily regimen, additional patients were enrolled to ensure a minimum of 22 patients were treated at the MTD to provide a 90% probability of detecting adverse events with an incidence of 10% and permit further assessment of pharmacokinetics, pharmacodynamic effects, and antitumor activity. Twice-daily dosing was also tested to explore the effect of dose fractionation and MTD.

Sequential cohorts of patients were treated with escalating doses of sonidegib once (100, 200, 400, 800, 1,000, 1,500, or 3,000 mg) or twice daily (250, 400, or 750 mg), continuously in a 28-day cycle. Twice-daily dosing was evaluated to address apparent solubility-limited absorption at doses  $>400$  mg once daily. A minimum of 3 evaluable patients were required to make dose-escalation decisions after completing cycle 1. Additional patients were enrolled to allow for dropouts and to better define the safety, pharmacokinetics, or pharmacodynamics of sonidegib at a given dose. Enrollment of patients with medulloblastoma and advanced BCC was allowed at previously well-tolerated doses during the dose-escalation phase.

A 2-parameter Bayesian logistic regression model for escalation with overdose control was used to guide dose

escalation decisions (15, 16). A DLT was defined as a significant adverse event or abnormal laboratory parameter adjudged to be Common Terminology Criteria for Adverse Events (CTCAE version 3.0) grade  $\geq 3$  in severity and considered unrelated to disease progression, intercurrent illness, or concomitant medications. The MTD was defined as the highest dose of sonidegib predicted to have  $< 25\%$  probability of a DLT rate of  $\geq 33\%$  during cycle 1 (first 28 days). After tolerating the assigned dose for at least 2 cycles, inpatient dose escalations were permitted. Dose escalation decisions were impacted by the emergence of late-onset, reversible grade 3/4 elevated serum creatine kinase (CK), occurring primarily during cycle 2.

### Safety evaluations

Safety was assessed according to CTCAE version 3.0 guidelines (17). Assessments included regular laboratory evaluations, physical examinations, vital signs, weight, and periodic electrocardiogram recordings. All patients were monitored for safety from the first dose until 28 days after the final dose. Additional monitoring, including weekly serum creatine kinase during cycle 2 and on the first day of subsequent cycles, was implemented.

### Pharmacokinetics assessments and analyses

**Blood sample collection and handling.** Blood samples for pharmacokinetic analyses were collected throughout the study. For the pharmacokinetic run-in period, serial blood samples were collected starting on day 1 (ending on day 5) at predose and 0.5, 1, 2, 4, 6, 8, 24, 48, 72, and 96 hours postdose. Serial blood samples were also collected on day 15 of cycle 1 at predose and 0.5, 1, 2, 4, 6, and 8 hours postdose. Blood samples were also collected predose on days 1, 8, 16, and 22 of cycle 1; days 1, 2, 8, 15, 16, and 22 of cycle 2; and day 1 of all subsequent cycles. Samples were processed and frozen at  $-70^{\circ}\text{C}$  within 90 minutes of the collection.

**Preparation and analysis of plasma samples.** Plasma samples were prepared using a protein precipitation extraction procedure, and sonidegib concentrations were determined using a validated liquid chromatography/tandem mass spectrometry (LC/MS-MS) assay using an API 5000 triple quadrupole mass spectrometer from AB Sciex equipped with an electrospray interface. Sample extracts were analyzed using gradient reverse-phase chromatography with a Capcell Pak C18 ACR,  $150 \times 4.6$  mm ID,  $5\text{-}\mu\text{m}$  particles (Shiseido Co Ltd.). The mobile phase consisting of water/0.1% ammoniac solution followed by acetonitrile/isopropanol (8:2, v/v) was pumped through the column at a flow rate of 1.0 mL/min. Positive-ion multiple reaction monitoring (MRM) with a labeled internal control and a lower limit of quantitation of 0.0247 ng/mL (using 0.050 mL of plasma) was used for detection. The MRM transition monitored for sonidegib, and the labeled internal standard was  $m/z$  486.07 to 428.08 and 490.07 to 432.08, respectively. The LC/MS-MS chromatograms of all analyzed baseline samples showed no interfering peaks, demonstrating selectivity of the method. Intraday and interday preci-

sion as represented by the coefficient of variation and accuracy as represented by the mean bias were within 20%. The validated method is suitable for the determination of sonidegib in human plasma.

**Pharmacokinetics assessments.** Pharmacokinetic parameters were calculated using noncompartmental methods with WinNonlin, version 5.2 (Pharsight). Peak plasma concentration ( $C_{\text{max}}$ ) and time to reach  $C_{\text{max}}$  ( $T_{\text{max}}$ ) were obtained from individual sonidegib concentration–time profiles. Area under the plasma concentration–time curve (AUC) values were calculated using the linear trapezoidal rule. Steady state was defined as a stable plasma trough concentration in at least 2 consecutive samples. Accumulation ratios were calculated by dividing the average plasma trough concentration at steady state by the trough concentration after the first dose.

### Biomarker and antitumor evaluations

Fresh or archival tumor samples were collected when available, and biopsies of normal skin were collected from all patients before sonidegib treatment, at the end of cycles 1 and 2, and within 14 days after the last dose. RNA was extracted from tissue samples and analyzed by reverse transcriptase-PCR (RT-PCR) to measure GLI1 expression and hedgehog pathway activation status, based on the 5-gene hedgehog signature assay (18, 19).

All potential sites of tumor lesions were evaluated by computed tomography, magnetic resonance imaging, or physical examination (locally advanced BCCs) at baseline and every 8 weeks. Antitumor activity was determined according to RECIST 1.0 (12) and the Neuro-Oncology Criteria of Tumor Response (medulloblastoma only; refs. 13 and 14). [ $^{18}\text{F}$ ]-fluorodeoxyglucose positron emission tomography (FDG-PET) was performed in a subset of patients at baseline, day 28 of cycles 1 and 2, and posttreatment to supplement RECIST assessments. Percent changes from baseline standardized uptake value (SUV) using the average over lesions per patient were determined for patients with at least one lesion  $\geq 2$  cm with a tumor-to-background ratio of  $\geq 2$ . Metabolic partial response was defined as a decrease of  $\geq 25\%$  in summed maximum SUV in the target lesion as per the recommendations proposed by Weber and colleagues (20).

### Statistical analyses

Demographics, safety, efficacy, and relevant pharmacokinetics and pharmacodynamic measurements were summarized using descriptive statistics and contingency tables. Study data included all patient data from the dose escalation and enrichment cohorts until all patients had completed at least 3 cycles of treatment or discontinued the study.

## Results

### Patient demographics and clinical characteristics

A total of 103 patients, comprising 73 and 30 patients on the once-daily and twice-daily schedules, respectively, were enrolled between March 2009 and June 2011. Overall, 16 patients with BCC and 9 patients with medulloblastoma

**Table 1.** Demographic summary and disease characteristics at baseline

Baseline characteristics	All patients (n = 103)
Age, median years (range)	59.0 (22–87)
Male sex, %	61.2
Primary site of cancer, n (%)	
Pancreas	19 (18.4)
Colorectal	18 (17.5)
Other gastrointestinal tumors <sup>a</sup>	8 (7.8)
BCC	16 (15.5)
Lung	10 (9.7)
Medulloblastoma	9 (8.7)
Genitourinary tumors <sup>b</sup>	5 (4.9)
Breast	3 (2.9)
Cutaneous melanoma	3 (2.9)
Other <sup>c</sup>	12 (11.7)
Prior antineoplastic therapies, n (%)	
Surgery	91 (88.3)
Radiotherapy	47 (45.6)
Systemic therapy <sup>d</sup>	96 (93.2)
Prior systemic therapies <sup>d</sup>	
1	20 (19.4)
2	22 (21.4)
>2	54 (52.4)
ECOG performance status, n (%)	
0	41 (39.8)
1	55 (53.4)
2	7 (6.8)

<sup>a</sup>Other gastrointestinal tumors included cholangiocarcinoma (4), stomach (1), gall bladder (1), esophageal (1), and small intestine (1).

<sup>b</sup>Genitourinary tumors included cervix (1), ovary (1), endometrial (1), prostate (1), and renal (1).

<sup>c</sup>Other included leiomyosarcoma (2), germ cell (2), mesothelioma (2), Merkel cell carcinoma (1), spindle cell carcinoma (1), osteosarcoma (1), adenocarcinoma of unknown primary (1), ciliary body melanoma (1), and ampulloma (1).

<sup>d</sup>Included chemotherapy, hormonal therapy, immunotherapy, and targeted therapy (1 patient with BCC was previously treated with the topical formulation of sonidegib).

were treated. Primary tumor site, previous antineoplastic therapies, and ECOG performance status of patients enrolled are listed in Table 1.

**Safety findings**

Sonidegib was generally well tolerated with typically mild (grade 1/2) adverse events (Table 2). Patients comprising the dose-decision sets are listed in Supplementary Table S1. Most common treatment-related grade 1/2 adverse events experienced by >10% of patients included nausea, dysgeusia, anorexia, vomiting, muscle spasms, myalgia, increased serum creatine kinase, fatigue/asthenia, and alopecia, char-

acterized by gradual thinning of the hair. Notable grade 3/4 adverse events occurring in <5% of all treated patients included weight loss, myalgia, hyperbilirubinemia, dizziness, and asthenia. There were no deaths because of drug-related toxicities. Dose reduction occurred in 17 patients (17%), mostly treated at doses >800 mg. Twenty patients (19%) permanently discontinued treatment because of adverse events, mostly associated with creatine kinase elevation (14 of 20). Reversible grade 3/4 serum creatine kinase elevation was considered to be dose limiting in 19 patients (18%) at doses ≥800 mg once daily and ≥250 mg twice daily (Supplementary Table S1). These DLTs tended to occur 3 to 6 weeks after treatment initiation in an exposure-dependent manner (Fig. 1). Because of the delayed onset, reports of DLTs initially seemed to be limited to high-dose cohorts; however, after further evaluation in expanded cohorts, 2 of 26 patients and 2 of 14 patients experienced DLTs at 800 mg once daily and 250 mg twice daily, respectively. Thus, these doses fulfilled the prespecified criteria for MTD. In most cases, elevated creatine kinase was associated with myalgia. However, some patients reported myalgia and muscle spasm without creatine kinase elevation. Treatment-emergent creatine kinase elevation resolved within 4 to 8 weeks of drug discontinuation. No concurrent renal dysfunction was observed in any patient. Of the patients with creatine kinase elevation, 8 resumed treatment on a reduced dose without recurrence. Eight of 19 patients with DLTs also experienced grade 3/4 adverse events, including increased aspartate aminotransferase, alanine aminotransferase, or myoglobin; muscular weakness; and myositis. No clinically significant changes in creatine kinase-myocardial B isoenzyme, suggestive of cardiac muscle injury, were noted. In 3 cases, the DLTs were reported as rhabdomyolysis, primarily based on elevated blood creatine kinase ± myoglobin levels without evidence of renal dysfunction. Creatine kinase elevation in these patients resolved following discontinuation of sonidegib. No additional therapy was required in 1 patient—the other 2 patients received sodium chloride (n = 1) or furosemide (n = 1). Treatment with sonidegib was not resumed in these patients.

**Pharmacokinetics**

Pharmacokinetic parameters were calculated for 102 patients based on the single-dose pharmacokinetic run-in and for 82 patients on day 15 of daily dosing. Mean sonidegib plasma concentration–time profiles following the pharmacokinetic run-in period before initiating continuous dosing are presented (Supplementary Fig. S2). Relevant pharmacokinetic parameters derived from the plasma concentration–time curves on pharmacokinetic run-in and day 15 of cycle 1 are summarized in Table 3. Sonidegib was absorbed after oral administration, with a median T<sub>max</sub> of 2 hours (range 1–48 hours) for all dosing regimens and doses combined. Sonidegib plasma exposure (C<sub>max</sub> and AUC) after single-dose administration increased dose proportionally from 100 to 400 mg and less than dose proportionally above 400 mg. After repeated once-daily dosing from 100 to 3,000 mg, C<sub>max</sub> and AUC on cycle 1,


Downloaded from <http://aacrjournals.org/linccancerres/article-pdf/20/7/1900/2024798/1900.pdf> by guest on 13 June 2024

**Table 2.** Most common adverse events (all grades,  $\geq 5\%$  incidence) suspected to be related to sonidegib treatment

Total adverse events (%) Grade 3/4 (%) <sup>a</sup>	Once-daily doses, mg						Twice-daily doses, mg				All (n = 103)	
	100 (n = 6)	200 (n = 6)	400 (n = 5)	800 (n = 26)	1,000 (n = 11)	1,500 (n = 9)	3,000 (n = 10)	250 (n = 14)	400 (n = 8)	750 (n = 8)		
Gastrointestinal toxicity												
Nausea	3	1	0	4	3	4	2	3	1	5	26 (25.2)	
Dysgeusia	1	1	0	5	3	3	5	6	3	3	30 (29.1)	
Anorexia	2	1	1	8	4	0	4	5	3	2	30 (29.1)	
Vomiting	1	1	0	3	1	1	1	2	1	2	13 (12.6)	
Diarrhea	0	0	0	2	0	0	1	1	1	2	7 (6.8)	
Constipation	0	1	0	1	1	0	1	0	0	2	6 (5.8)	
Muscle spasms	2	2	0	9	3	4	0	5	4	4	33 (32.0)	
Myalgia	0	1	0	4	3	2	2	3	0	2	17 (16.5)	
Blood creatine kinase increased	1	1	0	7	4	3	4	3	4	6	33 (32.0)	
Increased transaminases <sup>b</sup>	0	0	0	2	2	2	3	2	2	5	19 (18.4)	
Fatigue/asthenia	5	2	0	6	4	3	2	6	2	1	15 (14.6)	
Alopecia	1	1	0	4	1	2	1	1	2	0	13 (12.6)	
Lethargy	0	0	0	3	1	0	1	1	0	1	7 (6.8)	

<sup>a</sup>Italicized numbers indicate grade 3/4 adverse events.

<sup>b</sup>Includes increased alanine aminotransferase or aspartate aminotransferase.



**Figure 1.** Relationship between sonidegib exposure and creatine kinase (CK) elevation. Sonidegib area under the plasma concentration–time curve from time 0 to 24 hours ( $AUC_{0-24\text{ h}}$ ) on day 15 of cycle 1 was plotted for each patient by dose cohort. Incidences of creatine kinase elevation were noted for each patient. Incidence of grade 3/4 creatine kinase elevation was associated with increased sonidegib exposure. Gray-filled diamonds indicate patients without grade 3 or 4 creatine kinase elevation; black-filled circles indicate patients who experienced grade 3 or 4 creatine kinase elevation. Black solid line indicates mean AUC.

day 15 increased approximately dose proportionally up to 400 mg and less than dose proportionally above 400 mg. After twice-daily dosing from 250 to 750 mg,  $C_{\text{max}}$  and AUC on cycle 1, day 15 increased less than dose proportionally. Twice-daily dosing resulted in higher systemic exposures compared with the equivalent once-daily regimen. The 7-day pharmacokinetics run-in phase implemented in this study was not long enough to allow for accurate estimation of the terminal half-life ( $t_{1/2}$ ), oral apparent clearance, or volume of distribution using noncompartmental methods. Based on the trough plasma concentration over time in patients monitored for a sufficiently long period without dose changes, steady state seemed variable and was achieved after 2 to 24 weeks of repeated dosing, with a median accumulation of 16-fold across the dose groups based on  $C_{\text{min}}$ . The estimated median effective elimination  $t_{1/2}$  of sonidegib, calculated on the basis of the accumulation ratio, was  $\approx 11$  days. The interpatient coefficients of variation for day 15  $C_{\text{max}}$  and AUC were 39% to 113% and 33% to 122%, respectively, across the dose range of 100 to 3,000 mg/day for all dosing regimens. At the MTD of 800 mg once daily and 250 mg twice daily, the day 15 exposures were similar, with coefficients of variation for  $C_{\text{max}}$  of 54% and 44% and AUC of 50% and 33%, respectively. The median accumulation ratio in 11 patients treated at 800 mg once daily was 16-fold. Increasing sonidegib dose and exposure were associated with increased odds of grade 3/4 creatine kinase elevation (Fig. 1 and Supplementary Fig. S3).

### Target inhibition

Sonidegib treatment caused a reduction in GLI1 mRNA expression in tumor and skin (Fig. 2). Target inhibition in the tumor, as measured by GLI1 expression, was more

pronounced than in the skin when both tissues were available for analyses (Supplementary Fig. S4). In general, the degree of target inhibition increased in a dose- and exposure-dependent manner, consistent with the utility of GLI1 expression as a pharmacodynamic marker for hedgehog pathway activation. However, in the limited number of samples analyzed, the reduction in GLI1 expression did not correlate with tumor response (data not shown).

### Antitumor activity

Ninety-nine patients (96%) were evaluable for tumor response. Partial tumor responses were observed over the dose range of 100 to 1,500 mg. Six of 16 patients with BCC (37.5%) and 3 of 9 patients with medulloblastoma (33%) achieved objective tumor responses (partial or complete response) according to RECIST and FDG-PET (Supplementary Table S2). In the 3 patients with medulloblastoma with a partial response, who were treated at 200, 800, and 1,500 mg once daily, duration of response ranged from 4 to 8 months. One patient with medulloblastoma, ages 25 years, with largely metastatic bone disease, did not have RECIST-measurable lesions; hence FDG-PET was used to monitor treatment effect. The metabolic partial response in this patient, maintained for 8 months, was associated with symptomatic improvement (reduction in bone pain). A patient with locally infiltrating BCC achieved a histologic complete response confirmed by multiple biopsies of the tumor and surrounding tissue after treatment at 400 mg twice daily (Fig. 3A). Partial responses were also observed in 5 patients with locally advanced or metastatic BCC (spread to the lungs), treated at 100, 800, or 1,000 mg once daily and 250 mg twice daily (Fig. 3B and C). Interestingly, the tumor burden of the patient who achieved a partial response at 250 mg twice daily continued to improve for several months after treatment discontinuation. In patients with BCC and medulloblastoma, there was a strong association between tumor response and hedgehog pathway activation, as determined by a 5-gene hedgehog signature RT-PCR assay (Supplementary Table S2; ref. 18). Best overall response of stable disease was observed in 24 patients (23%), with duration of stable disease  $> 6$  months in 3 patients with lung adenocarcinoma, spindle cell sarcoma, and BCC.

### Discussion

Continuous daily oral administration of sonidegib exhibited an acceptable safety profile, exposure-dependent target inhibition, and antitumor activity. The vast majority of adverse events were mild to moderate in severity. Treatment-related adverse events were manageable and reversible after discontinuation of drug. The majority of treatment-related adverse events in this study have been similarly observed with other SMO inhibitors in phase I studies in patients with advanced solid tumors (3, 8). The toxicity profiles of these agents cannot be directly compared in the absence of head-to-head trials; however, the most commonly reported adverse events in  $>10\%$  across the agents

**Table 3.** Summary of sonidegib pharmacokinetic parameters after a single dose on day 1 of pharmacokinetic run-in and repeated doses on day 15 of cycle 1

Pharmacokinetic run-in				
Dose, mg	N	C <sub>max</sub> , ng/mL mean (SD; CV%)	AUC <sub>0-168 h</sub> , ng × h/mL Mean (SD; CV%)	T <sub>max</sub> , h <sup>a</sup> Median (min-max)
100 once daily	6	85.8 (52.3; 61)	1,880 (1,150; 61)	2 (1-24)
200 once daily	6	160 (115; 72)	3,670 (2,130; 58)	2 (2-48)
400 once daily	5	267 (239; 90)	7,450 (8,530; 115)	4 (4-4)
<b>800 once daily<sup>b</sup></b>	<b>25</b>	<b>430 (381; 89)</b>	<b>7,870 (6,950; 88)</b>	<b>4 (1-27)</b>
1,000 once daily	11	322 (258; 80)	7,400 (6,340; 86)	2 (1-4)
1,500 once daily	9	376 (199; 53)	12,600 (7,110; 56)	4 (2-24)
3,000 once daily	10	429 (237; 55)	11,800 (11,200; 95)	2 (1-8)
<b>250 twice daily<sup>b</sup></b>	<b>14</b>	<b>150 (111; 74)</b>	<b>3,220 (2,320; 72)</b>	<b>2 (1-4)</b>
400 twice daily	8	334 (300; 90)	7,530 (7020; 93)	4 (2-4)
750 twice daily	8	226 (180; 80)	6,920 (7110; 103)	3 (1-23)
Day 15, cycle 1				
Dose, mg	n <sup>c</sup>	C <sub>max</sub> , ng/mL Mean (SD; CV%)	AUC <sub>0-24 h</sub> , ng × h/mL <sup>c</sup> Mean (SD; CV%)	T <sub>max</sub> , h <sup>a</sup> Median (min-max)
100 once daily	3	155 (63.4; 41)	2,690 (1,340; 50)	4 (2-6)
200 once daily	5	269 (163; 61)	5,920 (3,890; 66)	4 (0-6)
400 once daily	4	558 (286; 51)	10,200 (5,880; 58)	13 (1-24)
<b>800 once daily<sup>b</sup></b>	<b>20</b>	<b>840 (457; 54)</b>	<b>12,800 (6,350; 50)</b>	<b>2 (1-6)</b>
1,000 once daily	8	1,230 (1400; 113)	15,200 (18,500; 122)	4 (2-6)
1,500 once daily	8	1,320 (657; 50)	27,400 (14,300; 52)	5 (2-24)
3,000 once daily	6	1,670 (1050, 62)	24,600 (8770; 36)	3 (0-21)
<b>250 twice daily<sup>b</sup></b>	<b>13</b>	<b>807 (353; 44)</b>	<b>14,500 (4780; 33)</b>	<b>2 (0-6)</b>
400 twice daily	7	864 (333; 39)	13,800 (6390; 46)	2 (0-8)
750 twice daily	8	1570 (1020; 65)	26,900 (17,300; 64)	4 (0-8)

Abbreviations: AUC<sub>0-168 h</sub>, area under the plasma concentration-time curve from time zero to 168 hours; AUC<sub>0-24 h</sub>, area under the plasma concentration-time curve from time zero to 24 hours; C<sub>max</sub>, maximum plasma drug concentration; T<sub>max</sub>, time to reach C<sub>max</sub>. AUC<sub>0-24 h</sub> for twice-daily doses are calculated as 2 × AUC<sub>0-12 h</sub>.

<sup>a</sup> Values are median (range) and arithmetic mean (SD; CV%) for all other parameters.

<sup>b</sup> Bold values represent maximum tolerated dose for once-daily and twice-daily doses.


<sup>c</sup> AUC analysis on cycle 1, day 15 included 3, 3, 4, 16, 6, 3, 4, 12, 5, and 6 patients from the 100, 200, 400, 800, 1,000, 1,500, and 3,000 mg once-daily and 250, 400, and 750 mg twice-daily dose cohorts, respectively.

include muscle spasms, dysgeusia, fatigue, and alopecia (3, 8).


Current understanding of the role for hedgehog signaling suggests that the observed slowly evolving diffuse alopecia, dysgeusia, and muscle-related events are likely mechanistic on-target toxicities (21-23). SMO inhibitors have been shown to induce muscle contraction and muscle fiber twitching in primary human muscle cells, which is thought to be due effects on calcium influx, thus providing a potential mechanism for the muscle spasms observed in patients treated with sonidegib in this study (23). Reversible dose-limiting creatine kinase elevation of skeletal muscle origin (based on total creatine kinase/creatinine-myocardial B ratio) occurred in 18% of patients across all doses (<10% at the MTD, 800 mg once daily), with no evidence of cardiac muscle injury. Overall, hyperCKemia (without evidence of renal impairment) was reported in ≈46% of patients with

normal creatine kinase at baseline. Six patients with creatine kinase elevation also had grade 3/4 increases in serum transaminases without significant changes in other liver function tests, thus suggesting skeletal muscle origin. High drug exposure was associated with increased odds of grade 3/4 creatine kinase elevations (Fig. 1 and Supplementary Fig. S3). Although resolution of creatine kinase levels was slower than expected for the known half-life of creatine kinase, it was not entirely consistent with the long half-life of sonidegib. Some patients had resolution of creatine kinase despite maintaining high drug concentrations. In addition, recurrence was not observed on retreatment at a reduced dose. For the 3 patients with DLTs documented as rhabdomyolysis, creatine kinase elevation resolved following discontinuation of treatment with supportive care (sodium chloride or furosemide in 2 of the 3 patients). Furosemide was administered as a precaution, apparently to boost

**Figure 2.** Glioma-associated oncogene homolog 1 (GLI1) fold change and percent inhibition in normal skin by dose cohort after sonidegib treatment. GLI1 expression was analyzed in patient skin specimens before and after treatment with sonidegib. Fold change from baseline was determined and plotted by dose cohort. Sonidegib treatment induced a dose-dependent decrease in GLI1 expression. Dotted lines represent 50%, 60%, and 90% mean inhibition.



urinary output in 1 patient, although there was no evidence of impaired renal function. Not surprisingly, there was no clear relationship between the incidence of muscle cramps/spasms and hyperCKemia, as many patients experience muscle cramps/spasms without creatine kinase elevation



**Figure 3.** Responses in patients with BCC treated with sonidegib. A, IHC of a 76-year-old male patient with BCC treated with 400 mg twice daily. Histologically confirmed complete response was noted after 4 months of treatment. Photographs (B) and IHC (C) of BCCs in a 55-year-old male patient with Gorlin syndrome treated with 800 mg once daily. Partial response was observed after  $\approx$ 6 months. Circles in A highlight the presence or absence of tumor tissue; arrows in A highlight fibrosis.

following SMO inhibitor treatments (3, 8). Other drugs with potential to cause toxic myopathy should be used in caution with SMO inhibitors (24).

The underlying reason for the relatively long half-life of sonidegib is unknown, although tight tissue and/or plasma protein binding can be speculated. High-affinity protein binding was also shown to contribute to the long half-life ( $>7$  days) of the SMO inhibitor vismodegib—a methanesulfonyl benzamide identified in a high-throughput screen (25). Sonidegib does not exhibit a time-dependent pharmacokinetic profile. The drug accumulation pattern over time and extent of accumulation at steady state are consistent with *in vitro* data showing lack of induction or time-dependent inhibition of CYP enzymes (10). Sonidegib displayed nonlinear pharmacokinetics at higher doses, likely because of solubility-limited absorption, and not because of dose-dependent metabolism as shown by parallel decline of the plasma concentration profile across the dose range. Solubility-limited absorption also contributed to the nonlinear pharmacokinetics observed for vismodegib, however, slow metabolic elimination was also a factor (25). Although twice-daily dosing provided a higher systemic exposure than equivalent once-daily doses, it did not seem to offer a clinically meaningful advantage over the once-daily regimen in this study. Therefore, the once-daily dosing regimen is currently recommended for further studies with sonidegib. However, the twice-daily dosing regimen may be considered in situations where a faster time to steady-state systemic concentration is desirable.

This proof-of-concept study demonstrated that sonidegib induced target inhibition and antitumor activity at well-tolerated drug exposures in patients with BCC and medulloblastoma, tumor types known to harbor activating mutations (2). Sonidegib exhibited dose- and exposure-dependent inhibition of GLI1 in tumor and normal skin biopsies. GLI1 inhibition at maximum drug exposure at steady state is expected to be higher than that observed at the end of cycle 1. Although GLI1 inhibition in other tumors was comparable to BCC (Supplementary Fig. S4), no objective responses were reported in these tumors. Similarly, GLI1



stromal expression in a patient with rectal cancer treated with saridegib in a phase I study was reduced (8); however, this patient did not respond to treatment. The lack of response in these patients is most probably because of differences in the tumor dependency on hedgehog signaling (i.e., ligand-dependent vs. ligand-independent). In the case of ligand-dependent tumors, other factors and signaling pathways may be involved in tumorigenesis—therefore, inhibition of hedgehog signaling alone may not be enough to induce a response. In phase I studies, both saridegib and vismodegib caused a reduction in GLI1 levels in approximately 74% of normal skin biopsies analyzed (3, 8). Taken together, these data suggest that GLI1 is an ideal marker for SMO inhibitor therapy, but not a marker for tumor response. Molecular alterations in other hedgehog pathway components in the patients who responded are unknown as mutational analyses were not conducted in this study; however, hedgehog pathway activity was assessed using the 5-gene hedgehog signature assay, an RT-PCR-based assay, in fresh-frozen paraffin-embedded tumor samples—a strong association between tumor response and activated hedgehog pathway was observed in patients with BCC and medulloblastoma (18, 19).

Similar responses in patients with advanced BCC (29%–58%) have been observed in other phase I and II studies of SMO inhibitors (3, 4). The wide range of responses in these studies may be due in part to differences in patient populations and the methods of tumor evaluation across studies. In particular, assessment of response in BCC is confounded by the presence of residual scarring or fibrosis, making the standard provisions of RECIST suboptimal.

To date, responses in medulloblastoma have been reported only for sonidegib and vismodegib (3, 18, 26–29). Importantly, all responses occurred in patients with hedgehog-activated medulloblastoma (18, 26–29). Complete and partial responses have been observed in patients with medulloblastoma in our study and in a phase I/II study of sonidegib in children with tumors thought to be dependent on hedgehog signaling (phase I) and children and adults with hedgehog-activated medulloblastoma (18). A dramatic but transient regression of systemic metastatic disease (primarily in the bone) was observed in an adult patient treated with vismodegib in the first-in-man phase I study and 3 of 20 adult patients achieved sustained responses in a phase II study in recurrent medulloblastoma (3, 27, 28). Antitumor activity was also observed in 1 pediatric patient with hedgehog-activated medulloblastoma treated with vismodegib in a phase I study (29).

In conclusion, sonidegib treatment at the MTD of 800 mg daily and 250 mg twice daily was well tolerated and demonstrated dose- and exposure-dependent target inhibition. The antitumor activity in BCC and medulloblastoma and mechanism-based toxicities observed demonstrate that

sonidegib effectively inhibits hedgehog signaling. These results support the ongoing development of single-agent sonidegib for treatment of advanced BCC and relapsed medulloblastoma, and further exploration in combination therapies in other cancers (30–33).

#### Disclosure of Potential Conflicts of Interest

H.A. Tawbi acted as a consultant/advisor for Novartis. J. Baselga acted as a consultant/advisor for Novartis and received research funding from Novartis. R. Dummer has acted as a consultant/advisor for received honoraria from Novartis. M. Moles, L. Yang, C. Granvil, E. Hurh, and K. Rose are employees of Novartis and have ownership interest. Y. Shou was an employee of Novartis and has ownership interest. D. Amakye was an employee of Novartis. No potential conflicts of interest were disclosed by the other authors.

#### Authors' Contributions

**Concept and design:** J. Rodon, H.A. Tawbi, J. Baselga, Y. Shou, L. Yang, C. Granvil

**Development of methodology:** H.A. Tawbi, J. Baselga, J. Sarantopoulos, Y. Shou, L. Yang, C. Granvil, D.D. Amakye

**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** J. Rodon, H.A. Tawbi, A.L. Thomas, R.G. Stoller, C.P. Turttschi, J. Baselga, J. Sarantopoulos, D. Mahalingam, Y. Shou, M.A. Moles, L. Yang, C. Granvil, R. Dummer, A.C. Mita

**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** J. Rodon, H.A. Tawbi, A.L. Thomas, C.P. Turttschi, J. Sarantopoulos, D. Mahalingam, Y. Shou, L. Yang, C. Granvil, E. Hurh, K.L. Rose, D.D. Amakye, R. Dummer, A.C. Mita

**Writing, review, and/or revision of the manuscript:** J. Rodon, H.A. Tawbi, A.L. Thomas, R.G. Stoller, J. Baselga, J. Sarantopoulos, D. Mahalingam, Y. Shou, M.A. Moles, L. Yang, C. Granvil, E. Hurh, K.L. Rose, D.D. Amakye, R. Dummer, A.C. Mita

**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** H.A. Tawbi, D. Mahalingam, A.C. Mita

**Study supervision:** H.A. Tawbi, J. Sarantopoulos, D. Mahalingam, M.A. Moles, D.D. Amakye, A.C. Mita

#### Acknowledgments

The authors thank P. O'Rourke from the Cancer Therapy and Research Center at The University of Texas, L. Felderer from the University Hospital of Zürich, and M. Beltran, R. Dienstmann, I. Braña, G. Argiles, and G. Sala from Vall d'Hebron Institut d'Oncologia in Barcelona, and V. Garcia-Patos from the Department of Dermatology, Hospital Universitari Vall d'Hebron in Barcelona for patient care and data collection. The authors also thank C. Emotte, T. Sharp, and D. Robinson from Novartis Pharmaceuticals Corporation for sample analysis, and J. Brechbiel and K. Miller-Moslin for medical editorial assistance.

#### Grant Support

Financial support for editorial assistance was provided by Novartis Pharmaceuticals Corporation. The Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas, is also funded by the Cancer Center Support grant P30CA054174. The University of Pittsburgh Cancer Institute shared resources that are supported in part by award P30CA047904 were used for this project. The UPCL-Clinical Translational Research Center supported by the Clinical Translational Science Institute under the award NIH/NCRR/CTSA Grant UL1 RR024153 was used for this project.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 21, 2013; revised December 3, 2013; accepted December 19, 2013; published OnlineFirst February 12, 2014.

#### References

1. Pasca di Magliano M, Hebros M. Hedgehog signalling in cancer formation and maintenance. *Nat Rev Cancer* 2003;3:903–11.
2. Teglund S, Toftgard R. Hedgehog beyond medulloblastoma and basal cell carcinoma. *Biochim Biophys Acta* 2010;1805:181–208.

3. Lorusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor GDC-0449 in patients with refractory, locally-advanced or metastatic solid tumors. *Clin Cancer Res* 2011;17:2502-11.
4. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. *N Engl J Med* 2012;366:2171-9.
5. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. *N Engl J Med* 2012;366:2180-8.
6. Erivedge prescribing information. 2012 [cited 2013 May 14] Available from: [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2012/203388lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf).
7. Siu LL, Papadopoulos K, Alberts SR, Kirchoff-Ross R, Vakkalagadda B, Lang L, et al. A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. *J Clin Oncol* 2010 ASCO Ann Mtg Proc 2010;28:abstr 2501.
8. Jimeno A, Weiss GJ, Miller WH Jr, Gettinger S, Eigl BJ, Chang AL, et al. Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. *Clin Cancer Res* 2013;19:2766-74.
9. Jamieson C, Cortes JE, Oehler V, Baccarani M, Kantarjian HM, Papayanidis C, et al. Phase I dose-escalation study of PF-04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies. *Blood ASH Ann Mtg Proc* 2011;118:abstr 424.
10. Pan S, Wu X, Jiang J, Gao W, Wan Y, Cheng D, et al. Discovery of NVP-LDE225, a potent and selective smoothened antagonist. *Am Cancer Soc Med Chem Lett* 2010;1:130-4.
11. Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. *Sci Transl Med* 2010;2:51ra70.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 2000;92:205-16.
13. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. *J Clin Oncol* 1990;8:1277-80.
14. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. *J Clin Oncol* 2010;28:1963-72.
15. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. *Stat Med* 1998;17:1103-20.
16. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. *Stat Med* 2008;27:2420-39.
17. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. *Semin Radiat Oncol* 2003;13:176-81.
18. Shou Y, Robinson D, Amakye D, Rose K, Cho Y, Ligon KL, et al. A five-gene Hedgehog signature developed as a patient preselection tool for Hedgehog inhibitor therapy in medulloblastoma. *Clin Cancer Res*. In press.
19. Amakye D, Robinson D, Rose K, Cho J, Ligon KL, Sharp T, et al. The predictive value of a 5-gene signature as a patient pre-selection tool in medulloblastoma for Hedgehog pathway inhibitor therapy. *Am Assoc Cancer Res Congress* 2012;72:abstr 4818.
20. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. *J Clin Oncol* 2003;21:2651-7.
21. Rittie L, Stoll SW, Kang S, Voorhees JJ, Fisher GJ. Hedgehog signaling maintains hair follicle stem cell phenotype in young and aged human skin. *Aging Cell* 2009;8:738-51.
22. Liu HX, Maccallum DK, Edwards C, Gaffield W, Mistretta CM. Sonic hedgehog exerts distinct, stage-specific effects on tongue and taste papilla development. *Dev Biol* 2004;276:280-300.
23. Teperino R, Amann S, Bayer M, McGee SL, Loipetzberger A, Connor T, et al. Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat. *Cell* 2012;151:414-26.
24. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. *J Am Coll Cardiol* 2002;40:567-72.
25. Graham RA, Lum BL, Cheeti S, Jin JY, Jorga K, Von Hoff DD, et al. Pharmacokinetics of hedgehog pathway inhibitor GDC-0449 in patients with locally-advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. *Clin Cancer Res* 2011;17:2512-20.
26. Geoerger B, Aerts I, Casanova M, Chisholm J, Hargrave D, Leary SES, et al. Updated results from a phase I study of LDE225, a smoothened antagonist, in pediatric patients with recurrent medulloblastoma or other solid tumors. *International Society of Paediatric Oncology meeting abstracts* 2012:abstr O037.
27. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. *N Engl J Med* 2009;361:1173-8.
28. Gajjar AJ, Gururangan S, Qaddoumi IA, Packer R, Goldman S, Prados M, et al. A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): a pediatric brain tumor consortium study (PBTC 25B). *J Clin Oncol* 2013 ASCO Ann Mtg Proc 2013;31:abstr 2035.
29. Gajjar A, Stewart CF, Ellison DW, Kaste S, Kun LE, Packer RJ, et al. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. *Clin Cancer Res* 2013;19:6305-12.
30. ClinicalTrials.gov. A phase II study of efficacy and safety in patients with locally advanced or metastatic basal cell carcinoma (BOLT). 2011 [cited 2013 May 14]. Available from: <http://ClinicalTrials.gov/show/NCT01327053>.
31. ClinicalTrials.gov. Efficacy, safety and pharmacokinetics of oral LDE225 in treatment of patients with nevoid basal cell carcinoma syndrome (NBCCS BCC). 2011 [cited 2013 May 14]. Available from: <http://clinicaltrials.gov/ct2/show/NCT01350115>.
32. ClinicalTrials.gov. A dose finding and safety study of oral LDE225 in children. 2010 [cited 2013 May 14]. Available from: <http://ClinicalTrials.gov/show/NCT01125800>.
33. ClinicalTrials.gov. A phase III study of oral LDE225 versus (vs) temozolomide (TMZ) in patients with hedgehog (Hh)-pathway activated relapsed medulloblastoma (MB). 2012 [cited 2013 May 14]. Available from: <http://www.clinicaltrials.gov/ct2/show/NCT01708174>.